Latest news with #Endeavor
Miami Herald
3 days ago
- Science
- Miami Herald
NASA crew readies for ISS mission launch on Thursday
July 26 (UPI) -- An international crew of four is readying for Thursday's planned launch of a NASA mission to the International Space Station after arriving at the Kennedy Space Center in Florida. Astronauts Zena Cardman and Mike Fincke, Japanese Aerospace Exploration Agency specialist Kimiya Yui and Roscosmos cosmonaut Oleg Platonov will travel from Kennedy Space Center's Launch Complex 39A to the ISS while aboard the SpaceX Crew Dragon Endeavour. Cardman is the mission's leader. The crew landed at Space Florida's Launch and Landing Facility at 1:12 EDT after leaving from Houston on Saturday morning. "We are absolutely joyed to be here at Kennedy Space Center," Cardman said upon the crew's landing. "This is the first moment when it's really starting to feel real," she said. "This is the beginning of a week when things will feel progressively more and more real as we approach our launch." Mission pilot Fincke said the mission gives him another chance to fly aboard a spacecraft named Endeavour. "One of the last times I landed at the [Florida launch and landing facility] was on space shuttle Endeavour," Fincke told media. "Now we get to go on another endeavor - a Dragon Endeavour," he said. The Endeavour name honors the HMS Endeavour, which British Capt. James Cook used to explore and chart the South Pacific from 1768 to 1771. A SpaceX Falcon 9 rocket will deliver the Endeavor into low Earth orbit, which will make the Crew Dragon spacecraft the most flown among SpaceX's fleet. Thursday's launch is scheduled at 12:09 p.m. EDT and would enable the Endeavor to dock at the ISS on Aug. 2 if the launch occurs as planned. The four crew members will join Expedition 73, which already is at the ISS. An Expedition 74 crew is scheduled to replace the Expedition 73 crew while the Crew 11 team is at the ISS. Copyright 2025 UPI News Corporation. All Rights Reserved.
UPI
3 days ago
- Science
- UPI
NASA crew readies for ISS mission launch on Thursday
1 of 5 | NASA Crew 11 Commander Zena Cardman addresses media after arriving at the Kennedy Space Center in Florida on Saturday. Photo by Joe Marino/UPI | License Photo July 26 (UPI) -- An international crew of four is readying for Thursday's planned launch of a NASA mission to the International Space Station after arriving at the Kennedy Space Center in Florida. Astronauts Zena Cardman and Mike Fincke, Japanese Aerospace Exploration Agency specialist Kimiya Yui and Roscosmos cosmonaut Oleg Platonov will travel from Kennedy Space Center's Launch Complex 39A to the ISS while aboard the SpaceX Crew Dragon Endeavour. Cardman is the mission's leader. The crew landed at Space Florida's Launch and Landing Facility at 1:12 EDT after leaving from Houston on Saturday morning. "We are absolutely joyed to be here at Kennedy Space Center," Cardman said upon the crew's landing. "This is the first moment when it's really starting to feel real," she said. "This is the beginning of a week when things will feel progressively more and more real as we approach our launch." Mission pilot Fincke said the mission gives him another chance to fly aboard a spacecraft named Endeavour. "One of the last times I landed at the [Florida launch and landing facility] was on space shuttle Endeavour," Fincke told media. "Now we get to go on another endeavor - a Dragon Endeavour," he said. The Endeavour name honors the HMS Endeavour, which British Capt. James Cook used to explore and chart the South Pacific from 1768 to 1771. A SpaceX Falcon 9 rocket will deliver the Endeavor into low Earth orbit, which will make the Crew Dragon spacecraft the most flown among SpaceX's fleet. Thursday's launch is scheduled at 12:09 p.m. EDT and would enable the Endeavor to dock at the ISS on Aug. 2 if the launch occurs as planned. The four crew members will join Expedition 73, which already is at the ISS. An Expedition 74 crew is scheduled to replace the Expedition 73 crew while the Crew 11 team is at the ISS.
Otago Daily Times
5 days ago
- Entertainment
- Otago Daily Times
Canterbury board game creator scores big win
Carl de Visser and his board game Endeavor: Deep Sea, which recently won the Kennerspiel des Jahres award in Germany. PHOTO: OLIVIA JUDD A Cheviot man has gone global with his board game creation, taking out the highest honour in the world of tabletop gaming. Carl de Visser has won the 2025 Kennerspiel des Jahres— the world's most prestigious award in the strategy board game industry, for his cocreation Endeavor: Deep Sea. The award, presented annually in Berlin, Germany, recognises excellence in complex board game design. Carl and his co-creator Jarratt Gray spent a year and a half designing the under-the-sea themed board game, which builds on the foundations of an earlier game created by the pair in 2009, called Endeavor, which Carl says is more colonial themed. ''We basically re-did it from scratch with some of the same mechanics,'' says Carl. ''This one you're leading an ocean institute and you go out and explore the sea, you start on the surface and go deeper and deeper underwater.'' In the game, players build a team to form their institute gaining access to new actions and challenges as they explore five different ocean depths. Wining the award was a full circle moment for Carl, who has followed the Kennerspiel for years, and even makes an effort to purchase the winning game each year. The awards are paid attention to worldwide, and has many global entries, however to be eligible to enter the awards, your game has to be for sale in Germany. Endeavor: Deep Sea is played internationally, and Carl says is most popular in Germany and the United States. ''This kind of board game is taken a bit more seriously over in Germany— I arrived in Berlin and went to a pharmacy, and they had a board game section in the pharmacy.'' Carl says winning the award has seen a huge spike in sales for the game. Next, Carl and his co-creator Jarratt are working on an expansion to the game, called Endeavor Deep Sea: Uncharted Waters, which Carl hopes will be released by the end of next year. Carl's game is able to be purchased online.
Business Wire
16-07-2025
- Business
- Business Wire
Endeavor BioMedicines Receives Orphan Drug Designation from the U.S. Food and Drug Administration and European Commission for Taladegib (ENV-101) for the Treatment of Idiopathic Pulmonary Fibrosis
SAN DIEGO--(BUSINESS WIRE)--Endeavor BioMedicines ('Endeavor'), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced that both the European Commission (EC) and the U.S. Food and Drug Administration (FDA) have granted Orphan Drug Designation to its investigational therapy, taladegib (ENV-101), for the treatment of idiopathic pulmonary fibrosis (IPF). Endeavor is currently enrolling patients in the Phase 2b WHISTLE-PF (Wound-remodeling Hedgehog-Inhibitor ILD Study Testing Lung Function Endpoints-PF) clinical trial of taladegib in IPF, a chronic, progressive lung disease with limited treatment options. Enrollment in the WHISTLE-PF trial is on track and expected to be completed in 2026. 'Receiving Orphan Drug Designation for taladegib in both the United States and European Union underscores the significant unmet medical need for patients with IPF,' said Lisa Lancaster, M.D., Chief Medical Officer, Endeavor BioMedicines. 'We are encouraged by the potential of taladegib to reverse the course of disease across multiple measures of IPF, which is a major step forward from current standard-of-care. I am very proud of our team, which is executing the Phase 2b WHISTLE-PF trial with a remarkable sense of purpose, driven by our mission to push the boundaries of what is possible and restore hope to patients and their families.' Orphan Drug Designation in the European Union (EU) is granted by the EC based on a positive opinion from the European Medicines Agency's Committee for Orphan Medicinal Products. It is intended to encourage the development of drugs that may provide significant benefit to patients suffering from rare, life-threatening diseases with a prevalence of not more than five in 10,000 in the EU. The designation provides special incentives for sponsors, including eligibility for protocol assistance and exemptions or reductions in certain regulatory fees, as well as 10 years of marketing exclusivity if the product is approved for the designated use. The FDA grants Orphan Drug Designation to drugs and biologics intended for the treatment, diagnosis or prevention of rare diseases or conditions affecting fewer than 200,000 people in the U.S. Orphan Drug Designation provides sponsors certain benefits, including financial incentives to support clinical development and the potential for up to seven years of market exclusivity for the drug for the designated orphan indication in the U.S. if the drug is ultimately approved for that use. About the WHISTLE-PF Trial The Phase 2b WHISTLE-PF clinical trial is a global, randomized, placebo-controlled study evaluating the therapeutic potential of taladegib in individuals with IPF (NCT06422884). The WHISTLE-PF trial will evaluate the efficacy of a range of taladegib doses through 24 weeks of treatment, characterize the investigational compound's safety and tolerability, assess its effect on patient reported outcomes and its effects on lung function, lung capacity and lung fibrosis as measured by chest high-resolution computed tomography. About Taladegib Endeavor's investigational drug taladegib is a Hedgehog (Hh) signaling pathway inhibitor. By binding to and inhibiting a key receptor in the Hh pathway, taladegib stops the abnormal accumulation of myofibroblasts that cause fibrosis. This may resolve the excessive wound-healing process seen in pulmonary fibrosis, improving lung volume and function. About Idiopathic Pulmonary Fibrosis IPF is a chronic, progressive lung disease that affects more than 150,000 adults in the United States. Although the exact cause of IPF is unknown, various environmental factors can deliver repeated injuries to lung cells that trigger abnormal wound-healing processes and life-threatening lung scarring. IPF is a chronic disease with limited treatment options and a very poor prognosis. The average life expectancy is three to five years after diagnosis. About Endeavor BioMedicines Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor's lead candidate, taladegib (ENV-101), is an inhibitor of the Hedgehog signaling pathway in development for fibrotic lung diseases, including idiopathic pulmonary fibrosis (IPF). More information is available at and on LinkedIn or X.
Yahoo
15-07-2025
- Business
- Yahoo
Deltatre Acquires Endeavor Streaming
Deltatre, the international provider of streaming, digital, data, and graphics solutions for the sports, media, and entertainment industries, will acquire Endeavor Streaming from Endeavor Group Holdings, Inc., the company announced on Tuesday. Terms of the deal were not disclosed, but Deltatre said it will be joining its product suite that includes D3 VOLT, FORGE and AXIS with Endeavor Streaming's pure-play OTT product VESPER to create a 'digital and streaming platform leader.' More from TheWrap News Corp Authorizes New $1 Billion Stock Buyback Program Deltatre Acquires Endeavor Streaming A Crackdown on the $10 Billion Drug Ad Market Could Hammer Linear TV CAA, Comcast Ventures Join $84 Million Funding Round for AI Firm Moonvalley As part of the acquisition, the companies will also unite their digital strategy, consulting, and direct-to-consumer growth marketing services. The transaction is expected to close in the third quarter of 2025, subject to customary closing conditions. The joint portfolio of clients includes the NFL, UFC, Sky, Rogers, NBA, WWE, MLB, BritBox, Bell Media, LIV Golf, ICC, World Rugby, and UEFA. 'Together, we are extremely well-positioned to lead at every level of the industry – and this investment underscores our commitment to broadening the value we bring to existing and future clients. Endeavor Streaming is a highly respected player in our industry and its offerings are a natural complement to our existing products and services,' said Andrea Marini, CEO of Deltatre. 'Endeavor Streaming has established itself as a trusted partner to the world's largest sports and media companies, as they transition their businesses from linear-driven experiences into a direct-to-consumer driven future,' said Fred Santarpia, President of Endeavor Streaming. 'With Deltatre, we look forward to delivering even greater opportunities to create value for our partners in growing audiences and revenue.' This news comes after Silver Lake closed its $25 billion deal to take Endeavor private in March. Endeavor first started exploring a potential sale of some of its events, including Frieze, the Miami Open and Madrid Open tennis tournaments, back in October. Endeavor also sold On Location, Professional Bull Riders and IMG to TKO Group Holdings in a $3.25 billion all-equity deal. Additionally, former Endeavor executive chairman Patrick Whitesell bought WME Sport's football division. Weil, Gotshal & Manges LLP is serving as legal advisor to Deltatre, and New Deal Advisors SpA is acting as its financial advisor. Latham & Watkins LLP is serving as legal advisor to Endeavor Group Holdings, Inc., and The Raine Group is acting as its financial advisor. The post Deltatre Acquires Endeavor Streaming appeared first on TheWrap. Sign in to access your portfolio
